A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer Meeting Abstract


Authors: Konner, J. A.; Fallon, K.; Pezzuli, S.; Iasonos, A.; Sabbatini, P.; Hensley, M.; Chiang, A.; Tew, W.; Spriggs, D.; Aghajanian, C.
Abstract Title: A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer
Meeting Title: 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 25
Issue: 18 Suppl.
Meeting Dates: 2007 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2007-06-20
Start Page: 279s
Language: English
ACCESSION: WOS:000455043701306
PROVIDER: wos
Notes: Meeting Abstract: 5523 -- Source: Wos